Clinical Trials Browser

Approved for marketing × Carcinoma, Medullary × pralsetinib × Clear all

NCT04204928 2021-08-13

Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC

Approved for marketing

Carcinoma, Non-Small-Cell Lung, Carcinoma, Medullary